
CAS 1422144-42-0
:Formula:C30H35N3O9S2
InChI:InChI=1S/C28H27N3O3.2CH4O3S/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24;2*1-5(2,3)4/h3-14,16,26H,15,17,29H2,1-2H3,(H,31,32);2*1H3,(H,2,3,4)/t26-;;/m1../s1
InChI key:QQDRLKRHJOAQDC-FBHGDYMESA-N
SMILES:CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C.CS(=O)(=O)O.CS(=O)(=O)O
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Benzoic acid, 2,4-dimethyl-, [4-[(1S)-1-(aminomethyl)-2-(6-isoquinolinylamino)-2-oxoethyl]phenyl]methyl ester, methanesulfonate (1:2)
CAS:Formula:C30H35N3O9S2Purity:97%Color and Shape:SolidMolecular weight:645.7436Netarsudil Dimesylate
CAS:Formula:C28H27N3O3·2CH4O3SColor and Shape:White To Off-White SolidMolecular weight:453.54 2*96.10Netarsudil mesylate
CAS:Netarsudil mesylate (AR-13324 mesylate) is a Rho-related protein kinase inhibitor used to study glaucoma and hypertension.Formula:C30H35N3O9S2Purity:99.7%Color and Shape:SolidMolecular weight:645.74Netarsudil Mesylate
CAS:(S)-4-(3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonateFormula:C30H35N3O9S2Purity:98%Molecular weight:645.74AR-13324 mesylate
CAS:Controlled ProductFormula:C28H27N3O3·2CH4O3SColor and Shape:NeatMolecular weight:645.744AR-13324 mesylate
CAS:AR-13324 mesylate is a pharmaceutical compound, which is a selective Rho kinase inhibitor derived from chemical synthesis with a specific mode of action targeting the modulation of aqueous humor outflow in the eye. Structurally, it is designed to inhibit the Rho-associated protein kinase (ROCK) pathway, which plays a crucial role in controlling various cellular functions including contraction, motility, proliferation, and apoptosis, specifically affecting the trabecular meshwork and uveoscleral pathway in ocular tissues.
Formula:C29H31N3O6SPurity:Min. 95%Molecular weight:549.64 g/mol








